SYNAPTIC PHARMACEUTICAL CORP
SC 13G, 1999-02-16
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: ROYAL CARIBBEAN CRUISES LTD, SC 13G, 1999-02-16
Next: STEIN MART INC, SC 13G/A, 1999-02-16



                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549






                    Under the Securities Exchange Act of 1934

                                  SCHEDULE 13G



             INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2
                    UNDER THE SECURITIES EXCHANGE ACT OF 1934



                       Synaptic Pharmaceutical Corporation
                       -----------------------------------
                                (Name of Issuer)


                                  Common Stock
                                  ------------
                         (Title of Class of Securities)



                                    87156R109
                                    ---------
                                 (CUSIP Number)


                                December 31, 1998
                                -----------------
             (Date of Event Which Requires Filing of this Statement)


Check the  appropriate  box to  designate  the rule  pursuant  to which  this
Schedule  is  filed:  
     |X| Rule  13d-1(b)  
     |_| Rule  13d-1(c)  
     |_| Rule  13d-1(d)


                                Page 1 of 6 Pages

<PAGE>

                                  SCHEDULE 13G

CUSIP No.87156R109                                            Page 2 of 6 Pages
- -------------------------------------------------------------------------------
1)       NAME OF REPORTING PERSON
         S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

         Gilder Gagnon Howe & Co. LLC
         13-3174112
- --------------------------------------------------------------------------------
2)       CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP            (a)   |_|

                                                                     (b)   |_|
- --------------------------------------------------------------------------------
3)       SEC USE ONLY

- --------------------------------------------------------------------------------
4)       CITIZENSHIP OR PLACE OF ORGANIZATION

         New York
- --------------------------------------------------------------------------------
                               5)  SOLE VOTING POWER
                                   13,300
         NUMBER                -------------------------------------------------
         OF                    6)  SHARED VOTING POWER
         SHARES                    None
         BENEFICIALLY          -------------------------------------------------
         OWNED BY              7)  SOLE DISPOSITIVE POWER
         EACH                      None
         REPORTING             -------------------------------------------------
         PERSON                8)  SHARED DISPOSITIVE POWER
         WITH                      761,600
- --------------------------------------------------------------------------------
9)       AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

         761,600
- --------------------------------------------------------------------------------
10)      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
         SHARES                                                           |_|
- --------------------------------------------------------------------------------
11)      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

         7.1%
- --------------------------------------------------------------------------------
12)      TYPE OF REPORTING PERSON

         BD
- --------------------------------------------------------------------------------

<PAGE>

                                  Schedule 13G

Item 1(a).   Name of Issuer:

Synaptic Pharmaceutical Corporation

Item 1(b).   Address of Issuer's Principal Executive Offices:

215 College Road
Paramus, NJ  07652

Item 2(a).   Name of Person Filing:

Gilder Gagnon Howe & Co. LLC

Item 2(b).   Address of Principal Business Office or, if None, Residence:

1775 Broadway, 26th Floor
New York, NY  10019

Item 2(c).   Citizenship:

New York

Item 2(d).   Title of Class of Securities:

Common Stock

Item 2(e).   CUSIP Number: 

87156R109

Item 3.      If this  statement is filed pursuant to  ss.ss.240.13d-1(b),  or
             240.13d-2(b) or (c), check whether the person filing is a:

               (a)  |X| Broker or Dealer  Registered Under Section 15 of the Act
                    (15 U.S.C. 78o)

               (b)  |_| Bank as defined in section 3(a)(6) of the Act (15 U.S.C.
                    78c)

               (c)  |_| Insurance  Company as defined in section 3(a)(19) of the
                    Act (15 U.S.C. 78c)

               (d)  |_|  Investment  Company  registered  under section 8 of the
                    Investment Company Act of 1940 (15 U.S.C. 80a-8)

               (e)  |_|     Investment     Adviser    in     accordance     with
                    ss.240.13d-1(b)(1)(ii)(E)


                                Page 3 of 6 Pages

<PAGE>

               (f)  |_| Employee  benefit plan or endowment  fund in  accordance
                    with ss.240.13d-1(b)(1)(ii)(F)

               (g)  |_| Parent  Holding  Company or control person in accordance
                    with ss.240.13d-1(b)(ii)(G)

               (h)  |_| Savings Association as defined in ss.3(b) of the Federal
                    Deposit Insurance Act (12 U.S.C. 1813)

               (i)  |_| Church plan that is excluded  from the  definition of an
                    investment  company  under  ss.3(c)(15)  of  the  Investment
                    Company Act of 1940 (15 U.S.C. 80a-3)

               (j)  |_| Group, in accordance with ss.240.13d-1(b)(ii)(J)

Item 4.  Ownership.

             (a)  Amount beneficially owned:  761,600

             (b)  Percent of class:  7.1%

             (c) Number of shares as to which such person has:

                     (i)  Sole power to vote or to direct the vote:  13,300

                     (ii) Shared power to vote or to direct the vote:  None

                     (iii) Sole power to dispose or to direct the disposition 
                           of:  None

                     (iv) Shared power to dispose or to direct the disposition 
                          of:  761,600

The shares reported include 729,100 shares held in customer  accounts over which
members and/or employees of the Reporting Person have discretionary authority to
dispose  of or direct the  disposition  of the  shares,  19,200  shares  held in
accounts owned by the members of the Reporting  Person and their  families,  and
13,300  shares held in the account of the  profit-sharing  plan of the Reporting
Person ("the Profit-Sharing Plan").

Item 5.  Ownership of Five Percent or Less of a Class.

Not applicable.


                                Page 4 of 6 Pages

<PAGE>

Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

         The owners of the accounts (including the Profit-Sharing Plan) in which
the shares  reported on this  Schedule are held have the right to receive or the
power to direct the receipt of dividends from, or the proceeds from the sale of,
such securities.

Item 7.  Identification and Classification of the Subsidiary Which Acquired the 
         Security Being Reported on by the Parent Holding Company.

Not applicable.

Item 8.  Identification and Classification of Members of the Group.

Not applicable.

Item 9.  Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

         By  signing  below I  certify  that,  to the best of my  knowledge  and
belief, the securities referred to above were acquired in the ordinary course of
business  and were not acquired for the purpose of and do not have the effect of
changing or  influencing  the control of the issuer of such  securities and were
not acquired in connection  with or as a participant in any  transaction  having
such purposes or effect.


                                Page 5 of 6 Pages

<PAGE>

                                    SIGNATURE


     After  reasonable  inquiry  and to the best  knowledge  and  belief  of the
undersigned,  the  undersigned  certifies that the information set forth in this
Statement is true, complete and correct.


                                         February 16, 1999        
                                         ----------------------        
                                             Date


                                         /s/ Walter Weadock
                                         ---------------------
                                             Signature


                                         Walter Weadock, Member  
                                         ----------------------  
                                             Name/Title


                                Page 6 of 6 Pages



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission